

Resource Summary Report

Generated by [RRID](#) on Aug 24, 2026

pMD2-VSVGmut

RRID:Addgene_182229

Type: Plasmid

Proper Citation

RRID:Addgene_182229

Plasmid Information

URL: <http://www.addgene.org/182229>

Proper Citation: RRID:Addgene_182229

Insert Name: VSVGmut

Organism: Vesicular Stomatitis Virus

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:35396484](#)

Vector Backbone Description: Backbone Size:4284; Vector Backbone:pMD2; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: Mutations originally described in Nikolic et al 2018: <https://www.nature.com/articles/s41467-018-03432-4>.

Plasmid Name: pMD2-VSVGmut

Relevant Mutation: K47Q, R354A

Record Creation Time: 20220422T222037+0000

Record Last Update: 20260815T081131+0000

Ratings and Alerts

No rating or validation information has been found for pMD2-VSVGmut.

No alerts have been found for pMD2-VSVGmut.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shim BH, et al. (2026) Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells. Cell reports, 45(6), 117510.

Gaglione SA, et al. (2026) Scalable TCR synthesis and screening enable antigen reactivity mapping in vitiligo. Immunity, 59(2), 477.

Xu EJK, et al. (2025) Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells. Science advances, 11(45), eadv2331.

Xu EJK, et al. (2024) Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells. bioRxiv : the preprint server for biology.